Integrated in silico–in vitro and pharmacokinetic profiling of Thymus vulgaris-derived metabolites targeting multidrug resistance pathways in extensively drug-resistant Acinetobacter baumannii (muks92)

<i>T. vulgaris</i> metabolites, particularly gamma-terpinene, exhibit multi-target inhibitory potential against resistance and virulence pathways in XDR <i>A. baumannii</i> (muks92), aligning <i>in-silico</i> interactions with measurable antibiofilm and ESBL attenuation <i>in vitro</i>. Given the predictive nature of docking/ADMET outputs, targeted enzyme kinetics, standardized MIC/MBC testing, cytotoxicity assays, and in-vivo validation are warranted before therapeutic translation.